CRIS Current Research Information System

FORNARI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.605
AS - Asia 2.215
EU - Europa 2.034
AF - Africa 140
SA - Sud America 111
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 1
Totale 7.124
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.579
SG - Singapore 769
CN - Cina 715
IT - Italia 577
GB - Regno Unito 326
DE - Germania 226
HK - Hong Kong 204
SE - Svezia 204
VN - Vietnam 176
NL - Olanda 132
IN - India 128
KR - Corea 92
RU - Federazione Russa 86
IE - Irlanda 83
FR - Francia 80
BR - Brasile 79
CH - Svizzera 71
UA - Ucraina 54
FI - Finlandia 51
BG - Bulgaria 50
CI - Costa d'Avorio 35
SC - Seychelles 35
JP - Giappone 32
ID - Indonesia 30
ZA - Sudafrica 28
EE - Estonia 25
TG - Togo 25
CA - Canada 18
AT - Austria 17
JO - Giordania 17
EU - Europa 15
PK - Pakistan 13
PL - Polonia 12
AR - Argentina 10
BE - Belgio 10
HR - Croazia 10
EC - Ecuador 9
BD - Bangladesh 8
MX - Messico 7
DZ - Algeria 5
IL - Israele 5
PE - Perù 5
ES - Italia 4
GR - Grecia 4
UZ - Uzbekistan 4
CZ - Repubblica Ceca 3
EG - Egitto 3
NG - Nigeria 3
TR - Turchia 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
IR - Iran 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LT - Lituania 2
MY - Malesia 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TH - Thailandia 2
TN - Tunisia 2
AM - Armenia 1
AZ - Azerbaigian 1
CL - Cile 1
CO - Colombia 1
DK - Danimarca 1
ET - Etiopia 1
HN - Honduras 1
IQ - Iraq 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
ML - Mali 1
NC - Nuova Caledonia 1
NO - Norvegia 1
OM - Oman 1
RO - Romania 1
SI - Slovenia 1
SR - Suriname 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.124
Salva come PNG Salva come JPEG
Città #
Singapore 537
Ashburn 352
Southend 285
Fairfield 257
Hefei 204
Bologna 203
Hong Kong 201
Chandler 184
Woodbridge 135
Seattle 121
Houston 118
Santa Clara 116
Wilmington 111
Beijing 100
Ann Arbor 95
Seoul 92
Dublin 83
Boardman 80
Princeton 78
Dallas 70
Bern 68
Cambridge 64
Sofia 50
Los Angeles 42
Helsinki 40
Ho Chi Minh City 39
Milan 36
Abidjan 35
Dong Ket 35
Hanoi 34
New York 31
Jacksonville 30
Nanjing 30
Padova 29
Westminster 27
Redondo Beach 26
Lomé 25
Tokyo 25
San Diego 23
Munich 22
Amsterdam 20
Buffalo 20
Jakarta 20
Jinan 20
Bengaluru 18
Berlin 18
Amman 17
Florence 17
Saint Petersburg 15
Chicago 14
Frankfurt am Main 14
Hebei 14
Nanchang 14
São Paulo 14
Turin 13
Verona 12
Zhengzhou 12
London 11
Orem 11
Vienna 11
Brussels 10
Düsseldorf 10
Modena 10
Phoenix 10
Pune 10
San Giorgio di Piano 10
Shenyang 10
Changsha 9
Guangzhou 9
Mülheim 9
Nuremberg 9
Warsaw 9
Council Bluffs 8
Da Nang 8
Falls Church 8
Forlì 8
Lahore 8
Lappeenranta 8
Rome 8
Taizhou 8
Bremen 7
Brooklyn 7
Bühl 7
Des Moines 7
Jiaxing 7
Montreal 7
Redmond 7
Toronto 7
Chengdu 6
Dearborn 6
Ferrara 6
Lauterbourg 6
San Francisco 6
Shanghai 6
Tongling 6
Xi'an 6
Yubileyny 6
Chennai 5
Denver 5
Falkenstein 5
Totale 4.742
Salva come PNG Salva come JPEG
Nome #
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 240
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 221
Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate 215
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 197
LncRNAs as novel players in hepatocellular carcinoma recurrence 193
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 191
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 180
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. 177
CDKN1C/P57 Is Regulated by the Notch Target Gene Hes1 and Induces Senescence in Human Hepatocellular Carcinoma. 171
MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer 167
Gut Microbiome Modulation in Hepatocellular Carcinoma: Preventive Role in NAFLD/NASH Progression and Potential Applications in Immunotherapy-Based Strategies 163
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma 160
MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma 159
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. 155
The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma 155
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma 154
MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma 154
F.N.27 NOTCH SIGNALLING CONTROLS PROLIFERATION AND SENESCENCE OF HUMAN HEPATOCELLULAR CARCINOMA 153
Direct antiviral treatments for hepatitis c virus have off-target effects of oncologic relevance in hepatocellular carcinoma 150
Oncogenic role of miR-483-3p at the IGF2/483 locus. 148
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. 148
In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. 145
Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response 142
Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research 141
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 139
p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma 138
TP53/MicroRNA interplay in hepatocellular carcinoma 137
Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. 136
Hepatic cancer stem cells: Molecular mechanisms, therapeutic implications, and circulating biomarkers 136
Design, Synthesis and Biological Evaluation of Pyrazole derivatives as Potential multikinase Inhibitors in Hepatocarcinoma. 134
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model 134
MicroRNAs in Animal Models of HCC 126
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. 125
MicroRNA as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much is missing? 123
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma 121
Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions 120
MicroRNA involvement in hepatocellular carcinoma. 119
The Natural Inhibitor of DNA Topoisomerase I, Camptothecin, Modulates HIF-1 alpha Activity by Changing miR Expression Patterns in Human Cancer Cells 118
Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. 114
Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma 111
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 110
Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate 104
null 101
MiR-122 targets serpinB3 and is involved in sorafenib resistance in hepatocellular carcinoma 94
Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming 87
MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma 85
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma 80
Notch signaling regulation in HCC: From hepatitis virus to non‐coding rnas 78
Animal models of hepatocellular carcinoma prevention 62
Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus 57
Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma 53
Local hypothyroidism favours the progression of rat preneoplastic lesions to HCC 49
Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma 47
MicroRNA and hepatocellular carcinoma: biology and prognostic significance 44
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic cencerogenesis 43
The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival 39
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated HCC patients. 22
CXCL3 is a target of miR-30e-3p and predicts tumor escape in sorafenib-treated HCC patients. 19
miR-30e-3p/CXCL3 axis predicts early tumor escape in hepatocellular carcinoma patients undergoing sorafenib treatment 16
Gut microbiome alterations and lenvatinib resistance in hepatocellular carcinoma: the role of Akkermansia muciniphila postbiotics in treatment enhancement 14
Towards precision medicine: a preliminary collection of patient-derived organoids for the screening of personalised therapies in hepatocellular carcinoma 9
Mir-30e-3p/CXCL3 axis is involved in sorafenib resistance of hepatocellular carcinoma through the modulation of the tumor immune microenvironment 6
The tumour suppressor miR-22 induces metabolic reprogramming through GLUT1 targeting and represents a possible biomarker of Sorafenib response in Hepatocellular Carcinoma 5
MiR-30e-3p plays a dual role in hepatocellular carcinoma and predicts tumour escape to sorafenib Treatment 3
MiR-22 downregulation activates HIF-1A pathway and induces tumour progression, metabolic reprogramming and sorafenib resistance in hepatocellular carcinoma 2
MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 2
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated hepatocellular carcinoma patients. 1
Totale 7.342
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.071
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.071
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021331 0 0 0 0 0 45 34 37 54 39 23 99
2021/2022853 45 20 44 75 60 39 12 120 28 82 215 113
2022/2023936 90 95 56 103 52 78 23 55 164 27 72 121
2023/2024375 40 51 12 47 41 80 8 17 12 27 13 27
2024/20251.506 79 211 126 101 159 48 110 36 37 168 111 320
2025/20261.947 370 378 335 263 350 251 0 0 0 0 0 0
Totale 7.342